Zhu [33] and other groups [34,35] have reported that small-molecule ligands targeting C9-HRE RNA GQ can significantly reduce RNA foci and DPRs levels, and thus ameliorate C9ALS/FTD pathology in vitro and in vivo. The gene discussed is C9; the disease is frontotemporal dementia.